Стоит ли избегать minoxidil succinoyl oligopeptide-143 при беременности? | VeriMom

What to use instead

Pregnancy-safe ingredients that serve a similar function:

Pregnancy-safe products to use instead

Products built around the safer ingredients above, scored "no known risks" or "low risk".

Mew mew tweet

100

Mew mew tweet Cedar Spruce Baking Soda Free

L'Occitane

100

L´Occitane Powder To-mousse Facial Exfoliator

Avero

100

Avero Solid Deodorant

Unknown

100

schmidts here now

Sustain Yourself

100

Sustain Yourself Natural Deodorant

Bitamin

100

Bitamin Natural Deodorant N'orange

Dr Teals's

99

Dr Teals's Aluminum Free Deodorant Charcoal

900care

99

Déodorant stick parfum embruns

HappySoaps

99

Happysoaps Neutraal

Routine

99

Routine The Curator

Безопасные альтернативы minoxidil succinoyl oligopeptide-143 при беременности | VeriMom

Ингредиенты — Ингредиенты

См. также

• Безопасен ли minoxidil succinoyl oligopeptide-143 при беременности?
• Безопасен ли minoxidil succinoyl oligopeptide-143 для малышей?
• Какие безопасные при беременности альтернативы minoxidil succinoyl oligopeptide-143?

FAQ

Безопасен ли minoxidil succinoyl oligopeptide-143 при беременности?

Minoxidil (6-(piperidinyl)-2,4-pyrimidinediamine-3-oxide) is listed as a substance that must not form part of the composition of cosmetics in EU Annexes (minoxidil and its salts appear in the prohibited list), which by your rules requires h≥2. Topical minoxidil is systemically absorbed in measurable amounts and there are case reports of effects in infants after dermal exposure; therefore a mechanism of systemic exposure is plausible. No SCCS/CIR opinion or harmonised H360/H361 specific to the peptide was found; evidence is via minoxidil data and regulatory prohibition. Sources: EU Annex listing, PubChem/minoxidil, EMA safety note on infant hypertrichosis.

Безопасен ли minoxidil succinoyl oligopeptide-143 при грудном вскармливании?

Minoxidil is a pharmacologically active systemic agent with reports of infant effects after maternal topical use and some evidence of transmission/infant exposure; regulatory guidance warns about infant hypertrichosis following skin contact. Thus breastfeeding safety is a concern (h=2). Mechanistic concern is demonstrated systemic exposure; measured transfer into milk is not well-quantified in public cosmetic dossiers, so exposure is graded as low but measurable for breastfeeding (e=1).

Безопасен ли minoxidil succinoyl oligopeptide-143 для кожи малыша?

For dermal contact with infants (0–3 yr) there are case reports of excessive hair growth in infants after parental topical minoxidil use/contact, and infants have higher dermal uptake (immature barrier and higher surface-area-to-weight). Therefore hazard and mechanism scores follow minoxidil (h=2, m=2) and exposure is increased (adult e=2 → infant e=3 per your rules). No infant-specific toxicology studies for the peptide were found; the concern is driven by the minoxidil parent compound and case reports.

Как VeriMom оценивает minoxidil succinoyl oligopeptide-143?

VeriMom оценивает minoxidil succinoyl oligopeptide-143 в 33/100 (высокий риск) на основе EU CosIng, классификаций ECHA и исследований PubMed.

Какие безопасные альтернативы minoxidil succinoyl oligopeptide-143 при беременности?

См. наш список безопасных альтернатив minoxidil succinoyl oligopeptide-143 с аналогичной функцией и классификацией без известных рисков.